London, May 2, 2026, 18:02 BST
- GSK’s Lynavoy has received the green light from Britain’s MHRA to treat itch associated with primary biliary cholangitis, a rare liver condition.
- That sign-off comes after U.S. regulators cleared it in March, and after a licensing agreement with Alfasigma that could bring in as much as $690 million.
- GSK shares slipped just days before this decision, as investors questioned the strength of its first-quarter earnings beat.
GSK plc has secured UK clearance for Lynavoy, its itch therapy for adults with primary biliary cholangitis. The green light gives the British pharma group another regulatory milestone in liver disease, coming just days after investors raised concerns about earnings momentum. The country’s Medicines and Healthcare products Regulatory Agency granted approval to GlaxoSmithKline UK Limited on May 1.
Timing is key here, as GSK looks to show its pipeline has muscle with Luke Miels newly at the helm. Investors have a straightforward benchmark: can he counterbalance the looming 2028 patent cliff for HIV drug dolutegravir, while steering GSK toward its 40-billion-pound sales target for 2031?
GSK hasn’t found much breathing room in the market lately. London shares ended Friday at 1,901 pence, off 1.43%, extending losses from earlier in the week—even after Q1 numbers topped estimates, investors zeroed in on one-off gains. Verso Investment Management’s James Eugene flagged “quality concerns” around the results, according to Reuters. Reuters
Primary biliary cholangitis, or PBC, hits the liver’s bile ducts, triggering an autoimmune attack that leaves bile acids to pile up in the bloodstream—a process believed to drive itching. Lynavoy, the oral tablet form of linerixibat, targets that problem. Taken twice daily, it’s designed to cut down the excess bile acids.
The MHRA pointed to results from the global Phase 3 GLISTEN trial, which enrolled 238 patients. Over a span of 24 weeks, participants were given either linerixibat 40 mg twice a day or a placebo. According to the regulator, those on the drug saw a marked drop in itching and reported better sleep, thanks to less sleep disruption from itching.
Julian Beach, serving as interim executive director of healthcare quality and access at the MHRA, described the sign-off as a “new treatment option.” He added that the agency plans to continue tracking the drug’s safety and how well it works as more patients receive it. Gov
Back in March, GSK picked up a U.S. green light for Lynavoy in cholestatic pruritus—severe itching tied to reduced bile flow—in adults with PBC. The company flagged Lynavoy as the first drug cleared in the U.S. for this indication. Executive Kaivan Khavandi described it then as a “much needed treatment option.” GSK
The UK ruling carries weight for GSK’s bottom line too. Back in March, the company handed global rights for linerixibat to Italy’s Alfasigma in a deal that could reach $690 million. As Reuters laid out, GSK gets $300 million upfront, another $100 million if the drug clears U.S. regulators, $20 million on European and UK approvals, and as much as $270 million if sales targets are met. Double-digit royalties, tiered by volume, are on top.
There’s competition, but the lineup is thin. Back in March, Reuters noted that Gilead’s Livdelzi and Ipsen’s Iqirvo address PBC but leave the itch untreated, whereas Mirum Pharmaceuticals is working on volixibat specifically for pruritus in PBC.
Approval alone doesn’t guarantee immediate adoption. The MHRA flagged that monitoring for safety and efficacy will continue, and there’s still uncertainty about financial returns—pricing, physician uptake, Alfasigma’s launch plans, and the results of other pending regulatory reviews, especially in Europe, all factor in.
GSK posted first-quarter sales of 7.63 billion pounds, keeping its overall numbers steady. Specialty medicines jumped 14%, and vaccines brought in 2.1 billion pounds. Core earnings per share landed at 46.5 pence. The drugmaker stuck to its 2026 targets, still expecting 3% to 5% turnover growth along with 7% to 9% increases in both core operating profit and core EPS.
The argument isn’t over yet. Miels maintains that GSK is pushing drug development forward, pointing to 10 late-stage trials in the pipeline for this year. But investors want more than a handful of approvals like Lynavoy; they’re looking for evidence these successes can become a bigger story, not just a collection of incremental gains.
